Visant Medical, Inc.

Visant Medical is creating Lacrifill?, a novel and proprietary gel for the treatment of dry eye disease. Dry eye disease (DED) is the most common reason for seeking medical care of the eye. Beyond the suffering endured by DED patients, it results in reduced productivity at work, with patients with severe DED using half their annual sick leave due to their condition. DED has a signi?cant impact on both direct and indirect healthcare costs; in the United States, the annual cost of dry eye management, treatment, and lost productivity is estimated to be as much as $55 billion. The best solution to dry eye disease is one that promotes the retention of the patient’s own tears; natural tears have complex chemistry and contain more than 1,500 enzymes. Visant Medical’s unique product accomplishes this by filling the patient’s tear ducts with a soft, malleable gel that conforms comfortably to the patient’s natural tear duct anatomy. The gel is made from a proprietary formulation of hyaluronic acid, a natural component of tears, that further lubricates the ocular surface as it breaks down. A treatment with Visant Medical's Lacrifill provides relief from dry eye disease for up to six months.

网站

https://www.visantmedical.com

Visant Medical, Inc.的外部链接

所属行业

医疗设备制造业

规模

2-10 人

总部

Menlo Park，CA

类型

私人持股

创立

2017

领域

Ophthalmology和Dry Eye Disease